Table 1 MSC-EXOs as miRNAs delivery system in cancer
MSC-EXOs | Type of cancer | miRNAs | miRNAs function | Route of administration | Explain | References |
|---|---|---|---|---|---|---|
AD-MSC-EXOs | Bladder cancer | miR-138-5p | Tumor suppressor | Subcutaneous injections | This method is an efficient delivery carrier for small molecule medications in vivo, and EXOs-carried miR-138-5p is a hopeful curative factor for BC therapy | [166] |
BM-MSC-EXOs | Liver cancer | miR-205–5p | Tumor suppressor | Subcutaneously injected | This technique has inhibitory efficacy on the development of liver cancer via controlling CDKL3 | [121] |
hUC-MSC-EXOs | Hepatoma | miR-451a | Tumor suppressor | – | HUC-MSC-EXOs miR-451a suppressed ADAM10 to inhibit the chemotherapy resistance, cell cycle transition, proliferation, cancer cell development, and progression, and increase apoptosis of Hepatoma cells | [167] |
hUC-MSC-EXOs | Wilms tumor | miR-15a-5p | Tumor suppressor | Subcutaneously injected | This miRNA delivered via hUC-MSCs-Exo downregulates SEPT2 expression and inhibits WT cell development in vivo and in vitro | [168] |
AD-MSC-EXOs | Triple-negative breast cancer (TNBC) | miR-381-3p | Tumor suppressor | – | EXOs-miR-381 suppressed the growth, migration, and invasion malignancy of breast cancer cells and increased their apoptosis in vitro | [122] |
BM-MSC-EXOs | Acute myeloid leukemia (AML) | miR-7-5p | Tumor suppressor | Injected via a tail vein | Exo-miR-7-5p downregulates OSBPL11 via inhibiting the phosphorylation of the PI3K/AKT/mTOR signaling pathway, thus suppressing AML growth and increasing apoptosis | [123] |
BM-MSC-EXOs | Breast cancer | LNA-anti-miR-142 | OncomiRs | Intravenous injection | BM-MSC-EXOs can successfully transport anti-miR-142-3p to decrease the miR-142-3p and miR-150 rates and enhance the transcription of the regulative target genes (APC and P2X7R) | [169] |
DP-MSC-EXOs | Breast carcinoma cells | miR-34a | Tumor suppressor | – | Genetically altered DP-MSCs were able to discharge of EXOs enriched with curative miRNAs and offered the possibility of use of EXO-based carrier for gene distribution | [170] |
BM-MSC-EXOs | Castration-resistant prostate cancer (CRPC) | miR-let-7c | Tumor suppressor | – | These miRNAs can be effectively loaded into BM-MSC-EXOs. Therapy without carrier or MSC-EXOs-entrapped miR-let-7c led to remarkable decreases in cell proliferation and development in CRPC cells | [124] |
BM-MSC-EXOs | Glioma | miR-146b | Tumor suppressor | Intratumoral injection | Administration of an intratumoral dose of 50 μg miR-146 loaded in BM-MSC-EXOs remarkably decreased glioma xenograft development in rat brains | [125] |
BM-MSC-EXOs | Glioblastoma Multiforme | miR-9 | OncomiRs | – | To inhibit miR-9, techniques were created with Cy5-tagged anti-miR-9. This method leads to enhanced apoptosis and caspase action | [171] |